# Nava Therapeutics

> Biotech developing next-generation lipid nanoparticle delivery systems.

## Why it is interesting

Stealth LNP platform play — a16z participated in an $89M Series A (2024) alongside GV, Versant, and F-Prime as RNA delivery remains a bottleneck.

## Profile

- **Stage:** series-a
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (2024): $89M with a16z, GV, F-Prime, Versant among investors (Endpoints News)
- Co-investors not in VCT directory: GV, Versant Ventures, Readout Capital

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/f-prime-capital

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/nava-therapeutics